2023-08-28 16:10:44 ET
Verastem ( NASDAQ: VSTM ) said it has entered into a collaboration deal with Chinese biotech GenFleet that allows it to license up to three drug candidates for commercialization outside of China.
Under the deal, GenFleet will receive $11.5M for the first oncology program, with the potential deal size for all three programs reaching $625.5M, excluding royalties. Verastem would be able to license a compound after it achieves certain Phase 1 testing milestones.
The three oncology programs target RAS pathway-driven cancers. GenFleet would retain the rights to commercialize the products in China.
Mass.-based Verastem’s lead drug candidates, avutometinib and defactinib, are in late-stage development for the treatment of various cancers.
More on Verastem
- RAMPing Up Hope: Verastem's Cancer Crusade
- Verastem: Updated Avutometinib Data Brings My Position Out Of Mothballs... Again (Rating Upgrade)
- Verastem to begin phase 3 trial of ovarian cancer combination therapy
- Biggest stock movers today: Virgin Galactic, Coherent, iRobot, Nikola and more
- Verastem Oncology stock down on raising $85M equity capital
- Verastem Oncology plans for stock and warrants offering
- Seeking Alpha’s Quant Rating on Verastem
- Earnings data for Verastem
For further details see:
Verastem, China's GenFleet to collaborate on RAS pathway-driven cancer drugs